India, March 10 -- Protagonist Therapeutics, Inc. (PTGX) closed trading at $55.95, up 45.40 percent or $17.41 during Monday's trading, after announcing positive topline results from its ANTHEM-UC Phase 2b study of icotrokinra.
The stock opened at $50.08 and has traded between $48.50 and $57.97, compared to a previous close of $38.35 on the Nasdaq. Current volume is 3.83 million shares, significantly above the average volume of 725,662. The stock's 52-week range is $24.22 to $57.97.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The investigational oral peptide, developed in collaboration with Johnson & Johnson, met its primary endpoint of clinical response in all dose groups for adults with moderatel...